Qdenga Evrópusambandið - íslenska - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - fjölmörgum - bóluefni - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Pyrukynd Evrópusambandið - íslenska - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Imjudo Evrópusambandið - íslenska - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Æxlishemjandi lyf - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Tremelimumab AstraZeneca Evrópusambandið - íslenska - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Dipentum Tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dipentum tafla 500 mg

atnahs pharma netherlands b.v. - olsalazinum natríum - tafla - 500 mg

Dipentum Hart hylki 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dipentum hart hylki 250 mg

atnahs pharma netherlands b.v. - olsalazinum natríum - hart hylki - 250 mg

Albuman Innrennslislyf, lausn 200 g/l Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

albuman innrennslislyf, lausn 200 g/l

prothya biosolutions netherlands b.v. - human serum albumin - innrennslislyf, lausn - 200 g/l

Albuman Innrennslislyf, lausn 40 g/l Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

albuman innrennslislyf, lausn 40 g/l

prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l

Cofact Stungulyfsstofn og leysir, lausn 500 a.e. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cofact stungulyfsstofn og leysir, lausn 500 a.e.

prothya biosolutions netherlands b.v. - factor ii human; factor vii human; factor ix human; factor x human - stungulyfsstofn og leysir, lausn - 500 a.e.

Lytgobi Evrópusambandið - íslenska - EMA (European Medicines Agency)

lytgobi

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.